H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. have begun the first of four Phase III trials of Lu AE58054 for the treatment of Alzheimer’s disease. Lu AE58054 is a selective 5-HT6 receptor antagonist with a different proposed mechanism of action than currently available Alzheimer’s medications. It focuses on the 5-HT6 receptor, a different approach from the amyloid and tau hypotheses that have underpinned much of the drug research to date on Alzheimer’s disease. Several doses of Lu ...